>
Switch to:

Antares Pharma Debt-to-Equity

: 0.24 (As of Jun. 2021)
View and export this data going back to 1996. Start your Free Trial

Antares Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $23.8 Mil. Antares Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2021 was $7.9 Mil. Antares Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2021 was $132.0 Mil. Antares Pharma's debt to equity for the quarter that ended in Jun. 2021 was 0.24.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Antares Pharma's Debt-to-Equity or its related term are showing as below:

NAS:ATRS' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.22   Med: 0.39   Max: 3.03
Current: 0.24

-3.22
3.03

During the past 13 years, the highest Debt-to-Equity Ratio of Antares Pharma was 3.03. The lowest was -3.22. And the median was 0.39.

NAS:ATRS's Debt-to-Equity is ranked lower than
59% of the 639 Companies
in the Medical Devices & Instruments industry.

( Industry Median: 0.16 vs. NAS:ATRS: 0.24 )

Antares Pharma Debt-to-Equity Historical Data

The historical data trend for Antares Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-Equity
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.74 0.64 0.86 0.39

Antares Pharma Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.70 0.39 0.37 0.24

Competitive Comparison

For the Medical Instruments & Supplies industry, Antares Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Antares Pharma Debt-to-Equity Distribution

For the Medical Instruments & Supplies industry and Healthcare sector, Antares Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Antares Pharma's Debt-to-Equity falls into.



Antares Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Antares Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2020 is calculated as

Antares Pharma's Debt to Equity Ratio for the quarter that ended in Jun. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antares Pharma  (NAS:ATRS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Antares Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma Business Description

Antares Pharma logo
Industry
Traded in Other Exchanges
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Greenleaf Peter director ONE MEDIMMUNE WAY GAITHERSBURG MD 20878
Smith Karen L. director C/O JAZZ PHARMACEUTICALS PLC 5TH FL, WATERLOO EXCHANGE, WATERLOO RD DUBLIN L2 4 L2
Powell Fred M officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Garrity Thomas J director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: GARRITY THOMAS J a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Apple Robert F director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Jacob Leonard S director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Graham Peter J officer: EVP General Counsel, Secretary 315 E. 72ND ST. APT 5E NEW YORK NY 10021
Gueth Anton director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: GUETH ANTON a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Samson Marvin director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: SAMSON MARVIN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Tursi James Patrick officer: EVP, Chief Medical Officer 400 ALEXANDER PARK DRIVE PRINCETON NJ 08540
Gonella Jacques director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
Muckenhirn Keith E officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447
Fickenscher James E officer: Senior Vice President & CFO C/O AUXILIUM PHARMACEUTICALS, INC. 640 LEE ROAD CHESTERBROOK PA 19087
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE 37TH FLOOR NEW YORK NY 10017

Antares Pharma Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)